These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 34496043)

  • 1. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID-19 Patients.
    Stader F; Battegay M; Sendi P; Marzolini C
    Clin Pharmacol Ther; 2022 Mar; 111(3):579-584. PubMed ID: 34496043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers.
    Calderón MM; Chairez CL; Gordon LA; Alfaro RM; Kovacs JA; Penzak SR
    Pharmacotherapy; 2014 Nov; 34(11):1151-8. PubMed ID: 25142999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
    Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
    Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
    J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tiered approach to evaluate the CYP3A victim and perpetrator drug-drug interaction potential for vonoprazan using PBPK modeling and clinical data to inform labeling.
    Mulford DJ; Ramsden D; Zhang L; Michon I; Leifke E; Smith N; Jones HM; Scarpignato C
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):532-544. PubMed ID: 36896795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling.
    Samant TS; Huth F; Umehara K; Schiller H; Dhuria SV; Elmeliegy M; Miller M; Chakraborty A; Heimbach T; He H; Ji Y
    Clin Pharmacol Ther; 2020 Sep; 108(3):575-585. PubMed ID: 32557601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
    Chen KF; Chan LN; Lin YS
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
    Thoueille P; Delfraysse M; Andre P; Buclin T; Decosterd LA; Fedeli C; Ustero P; Calmy A; Guidi M;
    BMC Pharmacol Toxicol; 2023 Sep; 24(1):47. PubMed ID: 37759315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects.
    Robertson SM; Davey RT; Voell J; Formentini E; Alfaro RM; Penzak SR
    Curr Med Res Opin; 2008 Feb; 24(2):591-9. PubMed ID: 18205997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
    Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine.
    Nyunt MM; Lu Y; El-Gasim M; Parsons TL; Petty BG; Hendrix CW
    Clin Pharmacol Ther; 2012 May; 91(5):889-95. PubMed ID: 22472986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19).
    Schoergenhofer C; Jilma B; Stimpfl T; Karolyi M; Zoufaly A
    Ann Intern Med; 2020 Oct; 173(8):670-672. PubMed ID: 32422065
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of CYP3A-mediated drug interaction via cytokine (IL-6) elevation for mosunetuzumab using physiologically-based pharmacokinetic modeling.
    Chen Y; Ma F; Jones N; Deng R; Li C; Li CC
    CPT Pharmacometrics Syst Pharmacol; 2024 Feb; 13(2):234-246. PubMed ID: 38050329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
    Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
    Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors.
    Guo J; Zhou D; Li Y; Khanh BH
    Biopharm Drug Dispos; 2015 Nov; 36(8):507-19. PubMed ID: 26081137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease-Drug-Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID-19 Patients with CYP2C19 Phenotypes.
    Wang P; Liu S; Yang J
    Clin Pharmacol Ther; 2024 Aug; 116(2):363-371. PubMed ID: 38429919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.
    Wagner C; Zhao P; Arya V; Mullick C; Struble K; Au S
    J Clin Pharmacol; 2017 Oct; 57(10):1295-1304. PubMed ID: 28569994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
    Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
    Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates.
    Umehara KI; Huth F; Won CS; Heimbach T; He H
    Biopharm Drug Dispos; 2018 Mar; 39(3):152-163. PubMed ID: 29451681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.